A New Dosing Regimen for Nivolumab Plus Ipilimumab in Advanced Melanoma
The CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg.
Bias for Patient-Reported Outcomes in Open-Label Cancer Trials: How Big of a Concern Is It?
The US Food and Drug Administration explored the possibility of such bias in a recent viewpoint published in JAMA Oncology.
Updated Trial for PSMA-Targeted Therapy in Metastatic Prostate Cancer Excites
The latest trial results are based on a larger patient population and were reported at the 2019 ASCO Genitourinary Cancers Symposium.
ARCHES Trial “Changes Practice” for Metastatic Hormone-Sensitive Prostate Cancer
The results of the double-blind, phase III trial were presented at the 2019 ASCO Genitourinary Cancers Symposium.
Concerns Raised About Patient-Reported Outcomes in CheckMate 214 Trial
An exploratory analysis showed that patients who received nivolumab plus ipilimumab had better patient-reported outcomes. Do the results hold up?
Variant Identified for Testicular Cancer Signals Heightened Risk for Later Cancers
Researchers identified two germline pathogenic variants in CHEK2 that may account for a minority of men diagnosed with testicular germ cell tumors.
The Long-Term Benefit of Pembrolizumab in PD-L1–Positive NSCLC
Results of the 2-year follow-up analysis of the pivotal KEYNOTE-024 trial were recently published in the Journal of Clinical Oncology.
Does Chemotherapy Increase the Risks of Myelodysplastic Syndrome and Acute Myeloid Leukemia?
The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions.
Potential Surrogate Endpoint in Prostate Cancer to Speed Up Clinical Trials
An analysis of a large, phase III trial investigated a potential surrogate endpoint for survival outcomes in prostate cancer patients receiving ADT.
KEYNOTE-028 Trial Unveils Biomarkers Linked to Pembrolizumab Efficacy
The results of the study add to the growing body of literature regarding potential biomarkers for response to immune checkpoint inhibitors.
Checkpoint Inhibitors: Effective in NSCLC Patients With Pre-existing Autoimmune Disease?
The results, described by an expert as “very interesting” and a “a bit surprising," focused on the impact of autoimmune antibodies on anti–PD-1 therapy.
Trial Failure Still Yields Insights for Uterine Leiomyosarcoma
Experts weigh in on valuable findings that can be gleaned despite the fact that the phase III trial did not generate clinically meaningful results.
Adjuvant Therapy Questioned for Patients With Small Pancreatic Tumors
Investigators evaluated whether patients with pancreatic ductal adenocarcinoma benefit from adjuvant therapy after surgery if the tumor is smaller than 1 cm.
Chemotherapy Toxicity Differs by Sex in Esophageal Cancer
A large pooled analysis of individuals with advanced esophageal cancer showed men and women have different side effects to chemotherapy.
Early Insights into Biosimilar Cost Savings in the United States
A recent study in JAMA Oncology examined the average daily cost of biosimilar filgrastim-sndz compared with the brand name biologic.